Add KFF vaccine hesitancy monitor

Thanks de-facto
ljl-covid · Dec 17, 2020 · d2af929 · d2af929
1 parent b656b67
commit d2af929
Showing 1 changed file with 1 addition and 0 deletions.
diff --git a/README.md b/README.md
@@ -271,6 +271,7 @@ Note that the WHO will generally be unable to make statements that their more pr
 * [Coronavirus Vaccine Update, July 7](https://blogs.sciencemag.org/pipeline/archives/2020/06/29/coronavirus-vaccine-update-june-29) by Derek Lowe nicely covers the "frontrunners" and also some lesser known vaccines, divided by type, with commentary; [Coronavirus Vaccine Roundup, Early September](https://blogs.sciencemag.org/pipeline/archives/2020/09/03/coronavirus-vaccine-roundup-early-september) follows up on that
 * [Vaccine Possibilities](https://blogs.sciencemag.org/pipeline/archives/2020/11/18/vaccine-possibilities) also by Derek Lowe, from November 2020, covers length of protection, effectiveness, possible mutations, demographics, safety, distribution and rollout
 * [The race for coronavirus vaccines: a graphical guide](https://www.nature.com/articles/d41586-020-01221-y), an introductory article on Nature
+* [KFF COVID-19 Vaccine Monitor](https://www.kff.org/coronavirus-covid-19/) tracks the public's attitudes towards COVID-19 vaccines, with polls on vaccine hesitancy among Americans
 * [Moderna’s Covid-19 vaccine is strongly effective, early look at data show](https://www.statnews.com/2020/11/16/modernas-covid-19-vaccine-is-strongly-effective-early-look-at-data-show/), with more than 94% efficacy and severe COVID-19 cases only in the control arm, at an interim point of the [COVE trial](https://www.modernatx.com/cove-study), as covered by an article on StatNews
 * [Pfizer-BioNTech COVID-19 vaccine and related biological product advisory committee briefing document](https://www.fda.gov/media/144246/download) announces that this vaccine meets the FDA success criteria, with vaccine efficacy after the booster dose at 95.0%, counting 8 COVID-19 cases in the vaccine group compared to 162 COVID-19 cases in the placebo group, with a 95% credible interval of 90.3% to 97.6%
 * [Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext), encouraging preliminary results from the Oxford/AstraZeneca adenovirus-vectored vaccine, showing an acceptable safety profile and strong immune response after a booster, while [Derek Lowe's "In The Pipeline" blog provides a critical commentary](https://blogs.sciencemag.org/pipeline/archives/2020/07/20/new-data-on-the-oxford-az-vaccine) on it; in November 2020 [Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext) was published showing that older adults develop similar levels of immune response as younger adults, and with fewer side effects, and [interim results showed an overall efficacy of 70%](https://blogs.sciencemag.org/pipeline/archives/2020/11/23/oxford-az-vaccine-efficacy-data), importantly divided into 62% for a group that received two full doses, and 90% for a group receiving a half dose followed by a full-dose booster, a division in two trial arms that [appears to have arisen accidentally](https://arstechnica.com/science/2020/11/astrazenecas-best-covid-vaccine-result-was-a-fluke-experts-have-questions/); later in December 2020, a study partly funded by AstraZeneca looks at [Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK](https://www.thelancet.com/lancet/article/s0140-6736(20)32661-1) and finds that the vaccine had an "acceptable" profile, although the lower-end confidence interval values for efficacy are revealed as 54.8% overall, of which 67.4% in the half-dose group and 41.0% in the full-dose group